References
- Butrans [Full Prescribing Information]. Stamford (CT): Purdue Pharma L.P.; 2014 [cited 2016 Sep]. Available from: https://www.butrans.com/hcpportal/f?p=BUTRANSRX:ISI
- Harris SC, Morganroth J, Ripa SR, et al. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017;129(1):69–80.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: ICH E14. 2005 May 12. [cited 2016 Dec 7]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf
- Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther. 2002;303:688–694.
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals: S7B. 2005 May 12 [cited 2016 Dec 7]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf
- Subutex (buprenorphine and naloxone) sublingual tablets [Full Prescribing Information]. Richmond (VA): Reckitt Benckiser Pharmaceuticals, Inc. 2016 [cited 2016 Mar 10]. Available from: http://www.accessdata.fda gov/drugsatfda_docs/label/2014/020733Orig1s014lbl.pdf
- Suboxone (buprenorphine and naloxone) sublingual tablets. Richmond (VA): Reckitt Benckiser Pharmaceuticals, Inc. 2014 12. [cited 2016 Dec 8]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020733Orig1s014lbl.pdf
- Zubsolv Sublingual Tablets [Full Prescribing Information]. New York (NY): Orexo US, Inc. 2015 8 [cited 2016 Dec 8]. Available from: https://www.zubsolv.com/wp-content/uploads/2015/01/Zubsolv FullPrescribingInformation.pdf
- Bunavail Buccal Film [Full Prescribing Information]. Raleigh (NC): BioDelivery Sciences International, Inc. [cited 2016 Dec 8]. Available from: http://www.bunavail.com/assets/pdf/ BUNAVAIL_Full_Prescribing_Information.pdf
- Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167:2469–2475.
- Poole SA, Pecoraro A, Subramaniam G, et al. Presence or absence of QTc prolongation in buprenorphine-naloxone among youth with opioid dependence. J Addict Med. 2016;10:26–33.
- Stallvik M, Nordstrand B, Kristensen O, et al. Corrected QT interval during treatment with methadone and buprenorphine–relation to doses and serum concentrations. Drug Alcohol Depend. 2013;129:88–93.
- Fareed A, Patil D, Scheinberg K, et al. Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up. J Addict Dis. 2013;32:244–251.
- Kao D, Bartelson BB, Khatri V, et al. Trends in reporting methadone-associated cardiac arrhythmia 1997–2011. Ann Intern Med. 2013;158:735–741.
- Kao DP, Haigney MCP, Mehler PS, et al. Arrhythmia associated with buprenorphine and methadone reported to the food and drug administration. Addiction. 2015;110:1468–1475.
- Meyer-Massetti C, Vaerini S, Ratz Bravo AE, et al. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharmacol. 2011;33:806–814.
- Freedman SB, Uleryk E, Rumantir M, et al. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Am Coll Emerg Phys. 2014;64:19–25.
- Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in Collaboration with the Heart Rhythm Society. J Pain. 2014;15:321–337.
- Duragesic [Full Prescribing Information]. Titusville (NJ): Janssen Pharmaceuticals, Inc; 2014 [cited 2016 Oct 31]. Available from: http://www.duragesic.com/assets/pdf/duragesic_0.pdf
- Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. Jama. 1993;269:2765–2768.
- Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42:409–419.
- Mozzicato P. Standardized MedDRA queries. Their role in signal detection. Drug Saf. 2007;30:617–619.
- Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14:343–357.
- DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177–196.
- Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002;25:381–392.
- Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–436.
- Van Puijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3–10.
- Sager PT, Gintant G, Turner JR, et al. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167(3):292–300.
- Colatsky T, Fermini B, Gintant G, et al. Stockbridge. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. J Pharmacol Toxicol Methods. 2016;81:15–20.